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Abstract
Objective—To outline methods for deriving and validating intensive care unit (ICU)
antimicrobial utilization (AU) measures from computerized data and to describe programming
problems that emerged.
Design—Retrospective evaluation of computerized pharmacy and administrative data.
Setting—ICUs from four academic medical centers over 36 months.
Interventions—Investigators separately developed and validated programming code to report
AU measures in selected ICUs. Antibacterial and antifungal drugs for systemic administration
were categorized and expressed as antimicrobial days (each day that each antimicrobial drug was
given to each patient) and patient-days on antimicrobials (each day that any antimicrobial drug
was given to each patient). Monthly rates were compiled and analyzed centrally with ICU patient-
days as the denominator. Results were validated against data collected from manual medical
record review. Frequent discussion among investigators aided identification and correction of
programming problems.
Results—AU data were successfully programmed though a reiterative process of computer code
revision. After identifying and resolving major programming errors, comparison of computerized
patient-level data with data collected by manual medical record review revealed discrepancies in
antimicrobial days and patient-days on antimicrobials ranging from <1% to 17.7%. The hospital
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for which numerator data were derived from electronic medication administration records had the
least discrepant results.
Conclusions—Computerized AU measures can be derived feasibly, but threats to validity must
be sought and corrected. The magnitude of discrepancies between computerized AU data and a
gold standard based on manual chart review varies, with electronic medication administration
records providing maximal accuracy.
Antimicrobial resistance rendering previously treatable infections unresponsive to most
drugs is a significant and growing public health concern.1,2 This threat has been recognized
in the most recent national action plan for the prevention of healthcare-associated infections
outlined by the Department of Health and Human Services,3 and calls for a coordinated
national effort to monitor resistance and implement prevention and control efforts have been
longstanding.1,4 The Infectious Diseases Society of America and the Society for Healthcare
Epidemiology of America recently published guidelines promoting the implementation of
antimicrobial stewardship interventions in hospitals.5 An integral component of evaluating
the impact of any of these strategies is the accurate and continuous measurement of
antimicrobial utilization over time.
The increasingly computerized processes of healthcare delivery have made the automated
acquisition of antimicrobial utilization data possible. Indeed, most modern hospitals have
universal computerization of laboratory, pharmacy, admission-discharge-transfer (ADT),
and patient demographic and financial data.
However, just as these data sources have been incorporated into fully functional electronic
health records for only a small minority of hospitals,6 the derivation of reliable and accurate
reports based on computerized hospital data has generally been difficult to achieve.7
Because these data are stored at each hospital or health system in disparate information
systems, procedures required for their collection, extraction, cleaning, validation, and
computation are often complex and error-prone.8 With regard to antimicrobial use measures,
specifically, published data that have used electronic data sources to derive these estimates
have almost exclusively relied on propriety measurement systems and the methods
underlying the acquisition, validation, and consolidation of such data have not been well
described.
We describe our efforts to demonstrate the feasibility and validity of obtaining uniform
measures of antimicrobial utilization in selected intensive care units (ICUs) in four academic
medical centers by accessing pharmacy and administrative data contained in computerized
data warehouses. Despite considerable expertise and relevant experience by healthcare
informatics specialists and investigators in accessing such data, we encountered a number of
problems that were largely unforeseen and, therefore, may be informative to the
development of a standardized approach to deriving antimicrobial measures from electronic
data.
Methods
Four tertiary-care, academic medical centers were recruited from institutions participating in
the current Prevention Epicenter Program,9 funded by the Centers for Disease Control and
Prevention (CDC), to participate in this study. The Institutional Review Boards of each
hospital approved the study protocols, and waived requirements for patient and physician
consent.
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Hospital Intensive Care Unit Types and Information Technology Resources
The characteristics of the participating facilities, respective data warehouses, and medication
ordering, dispensing, and administration systems are outlined in Table 1. Descriptions of
these data warehouses have been provided elsewhere.8,10–12 Antimicrobial use data for
selected ICUs in each hospital over a 36-month time period (July 2004 – June 2007) were
acquired, analyzed, and validated separately at each institution before being sent to one
central Epicenter [Chicago Epicenter (DNS)] for collation and final analyses.
Antimicrobial use numerators (described below) were computed from varying electronic
data sources (Table 1). For Hospital A, whose pharmacy information system vendor
changed during the study period, the numerator data source changed from pharmacy
dispensing to computerized physician order entry (CPOE) data. Hospitals B, C and D
obtained numerator data from the electronic medication administration record (eMAR), from
pharmacy dispensing data and from CPOE data, respectively. Although eMARs were used
to document medication administration in three of the four hospitals, eMAR data were
available in a format amenable to analysis only at hospital B, which was able to distinguish
antimicrobial doses that were administered from those that were ordered but not
administered for any reason (e.g., because of doses held or refused). Denominator data (ICU
patient-days) were derived from the same data sources as those from which numerator data
were computed in all hospitals, with the exception of Hospital A where ADT data sources
had to be queried separately after the change in pharmacy information system vendors.
Antimicrobial Use Measures
The primary numerator measure for antimicrobial use was antimicrobial days, defined as
calendar days on which patients received each antibacterial or antifungal agent given by
intravenous (IV) or oral administration. For example, one patient given two drugs for 5 days
accrued 10 antimicrobial days. Drugs available in injectable, oral, or other systemically-
administered form were counted just once per day irrespective of route of administration.
Secondary numerator measures of antimicrobial use included patient-days on antimicrobials,
antimicrobial starts, antimicrobial courses, and defined daily doses (Table 2). Our
“antimicrobial days” have the same meaning as the “days of therapy” reported by Polk and
colleagues13; however, we’ve avoided this latter term because of its resemblance to “patient-
days on antimicrobials.” The programming logic used to compute numerator events from the
different data sources is summarized in Table 3. Antimicrobial use measures were summed
in each ICU for each calendar month over the study period and for each of the antimicrobial
agents and predefined drug classes (Table 4).
Antimicrobial use rates were calculated using ICU patient-days as the denominator. An ICU
patient-day was attributed to each patient occupying an ICU bed at midnight of each day, as
previously recommended14, so that events occurring on ICU admission days were counted
while those occurring on the day of ICU discharge were not.
Data validation
The investigators participated in regular teleconference calls to discuss problems with
programming and data collection, providing a forum for shared learning as problems
encountered at one institution were evaluated in the context of experience at the others.
Inspection of data derived from draft program code for face validity sometimes identified
the presence of programming errors before more detailed validation efforts were begun,
prompting detailed examination of programming code to pinpoint and correct programming
flaws, and subsequent validation studies to confirm data validity.
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Each hospital used two methods to systematically validate their data. First, to measure how
accurately medication administration records reflected actual medication administration to
patients, convenience samples of at least 100 intravenous antimicrobial doses scheduled for
administration in study ICUs were prospectively audited and observed at the bedside for
timeliness of administration using the method of Itokazu, et al.15 The results (timely dose
administration or not) were compared with the disposition of the dose as registered in the
medication administration records. Second, retrospective validation studies were conducted
by assembling cohorts of randomly selected antimicrobial recipients from each of the ICUs
during the study period and comparing counts of numerator events compiled by applying
draft computer queries to these cohorts with manual review of the same patients’ medication
administration records, our gold standard. After identifying and correcting programming
errors, numerator counts derived via revised program code and manual chart review were
applied to new cohorts of antimicrobial recipients and results compared until no new
programming errors could be identified.
Results
Investigators at the four participating institutions were able to generate antimicrobial
utilization data for each of the selected ICUs over the first 24 months of the 36-month study
period and reported preliminary intra- and inter-ICU antimicrobial use rate comparisons.16
However, preliminary retrospective and prospective validation studies revealed major
discrepancies between numerator counts that substantially biased the preliminary results and
prompted careful review of the code used in the computer queries for systematic error by
programmers and investigators. A summary of the programming errors is provided in Table
5. These errors were detected after inspection of the resulting reports suggested a lack of
face validity or after detection of inconsistencies between computerized reports of patient-
level data and charted medication administration record entries during retrospective
validation.
After identifying and correcting all identifiable programming errors, numerator counts
derived via revised program code and manual chart review were applied to new cohorts of
antimicrobial recipients and results compared until no new programming errors could be
identified. The discrepancies between computer-derived and manual counts of antimicrobial
days and patient-days on antimicrobials presented in Table 6 reflect these final comparisons.
The retrospective validation studies revealed variable levels of discrepancy by institution
between numerator counts derived from application of final computer queries and manual
review of medication administration records. Overestimation of counts of antimicrobial days
and patient-days on antimicrobials generated by computer code were < 1% at hospital B,
where antimicrobial utilization was computed from eMAR data. By contrast, programming
of computerized pharmacy dispensing data at hospital C, where delayed delivery of paper
medication orders from ICUs to pharmacy may have led to antimicrobial dispensing after
drug discontinuation or patient discharge orders were written,15 counted 17.7% more and
14.5% more antimicrobial days and patient-days on antimicrobials, respectively, than
manual record review did. Use of CPOE data to derive numerator antimicrobial measures at
hospitals A and D generated intermediate levels of discrepancy (Table 6).
Prospective bedside observations of the intravenous administration of routinely scheduled
antimicrobial doses revealed > 95% concordance between the observed outcomes of dose
administration events and the corresponding dose administration status recorded in the
MARs in all study ICUs (data not shown).
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Our findings show that derivation of standardized patient-level measures of antimicrobial
utilization from a sample of hospitals with disparate computerized pharmacy systems is
feasible. However, our experience highlights a few important issues related to the use of
computerized data sources to derive and report hospital antimicrobial utilization rates.
First, inter-institutional differences in pharmacy computer systems and available data
sources (Table 1) necessitated the use of institution-specific computing strategies (Table 3),
contributing to varying levels of fidelity between antimicrobial utilization results obtained
by application of computer code versus manual review of patient records (Table 6). Until
greater uniformity of hospital data systems is achieved or until valid antimicrobial
measurement programs are included within commercial and governmental hospital
pharmacy computer systems, institution-specific strategies for data programming, validation
and interpretation will have to be developed to ensure that accurate and comparable
measures of antimicrobial utilization data are derived and reported across hospitals.
Second, we found that programming of antimicrobial utilization measures based on
computerized pharmacy and administrative data was complex and error-prone. Despite
considerable experience in querying and analyzing computerized data from our respective
institutions,8,10–12 we made important errors in our initial attempts at deriving these
antimicrobial utilization measures (Table 5). Our need to adopt separate, institution-specific
computing strategies (Tables 1 and 3) and the complexities of computerized medical
records, in general,17 and of pharmacy data, in particular,8 likely contributed to these
problems. However, many of these mistakes stemmed from conceptual misunderstandings
and inadequacies in communication between clinician- investigators and informaticists
whose mitigation requires careful application of basic tenets of multidisciplinary
collaboration and data review and validation (Table 7). Complementary methods –
assessment of face validity, review of procedures for developing computer code and
retrospective validation procedures – were necessary to fully identify and correct these
errors, highlighting the importance of adopting a careful, systematic approach to collecting
and validating data from electronic health records.
Third, after maximally validating program code in our respective institutions, we measured
variable levels of over-estimation of computed numerator counts compared to a gold
standard based on retrospective medical record review (Table 6). These discrepancies likely
reflect inter-institutional variation in efficiency and coordination of medication ordering,
distribution and administration procedures.15,18 In particular, in hospital C which had the
highest level of discrepancies, delays in transport of paper medication orders to a centralized
pharmacy may have contributed to delayed pharmacy response to ordered changes in patient
antimicrobial regimens, leading to pharmacy dispensing of antimicrobial doses to the ICU
that were not administered and therefore omitted from the MAR (Tables 1, 3 and 5). By
contrast, use of bedside charting of eMAR data for both computer-derived and manually
collected numerator data in hospital B doubtlessly accounted for the high affinity between
data obtained through these different sources. Our results suggest that eMAR is the most
accurate source for pharmacy numerator data in hospitals where it is in use; however, this
finding requires confirmation from other institutions. Measures based on pharmacy
dispensing or physician orders, being further removed from the antimicrobial administration
event, are more likely to overestimate actual utilization.
The optimal metric for reporting hospital antimicrobial utilization is unclear.19–23 We chose
antimicrobial days and patient-days on antimicrobials (Table 2) as primary numerator
measures because they provide complementary information on the intensity and breadth of
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ICU antimicrobial use,23 they are minimally affected by variation in antimicrobial dosing
regimens and they should be readily extractable, given the current widespread availability of
detailed, patient-specific computerized pharmacy data within U.S. hospitals. Previous
studies have used “days of therapy,”13 analogous to our antimicrobial days, to rank and
assess secular trends in antimicrobial utilization in an alliance of 22 U.S. academic health
centers and in 130 U.S. hospitals.24,25 However, those analyses were based on charge and
billing data rather than the pharmacy dispensing, physician order or eMAR data that we
employed. Also, the specific methods – proprietary in one instance – were not detailed and
validation efforts were limited.24,25
Older U.S. and European antimicrobial utilization surveys, performed where detailed,
patient-specific data may not have been available, have used conversion factors such as the
defined daily dose (DDD) or recommended daily dose 26,27 to estimate patient-level
antimicrobial use from aggregate antimicrobial use and census data to make inter-
institutional or international comparisons,27–29 analyze secular trends,29,30 and correlate
antimicrobial use with antimicrobial resistance.31–33 However, pharmacy reports of
aggregate antimicrobial utilization may substantially overestimate actual use in hospitals
with poorly coordinated mechanisms of medication ordering, distribution and
administration.15 Moreover, DDDs underestimate patient-level exposure to drugs requiring
renal dose adjustment,34 overestimate the use of antimicrobials for which the conversion
factor is lower than doses that are commonly prescribed,13,35,36 and do not apply to most
pediatric patients.13
Adaptation of programming approaches to the disparate information systems and data
sources available in each institution will be a formidable challenge that will require
understanding and avoiding potential errors that can impede the valid and efficient
measurement of antimicrobial use. The CDC is currently revising the data submission
requirements for the Antimicrobial Utilization component of the National Healthcare Safety
Network (NHSN) to receive standardized summary measures from eMAR systems directly.
This may represent the most effective approach to achieving accurate centralized collection,
analysis and reporting of antimicrobial utilization measures from multiple institutions.37
Application of methods similar to ours by these and other surveillance efforts will be
instrumental in achieving the widespread availability of valid and efficient measurements of
antimicrobial utilization.
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Table 2
Numerators Used in Antimicrobial Utilization Measures and Their Definitions
Measure Definition Example
Antimicrobial days Sum of the calendar days on which each
antimicrobial was administered
2 drugs given for 5 days followed by a different drug
given for 5 days to one patient = 15 antimicrobial days
Patient-days on antimicrobials Sum of the calendar days on which one or more
antimicrobial drugs was administered
2 drugs given for 5 days followed by a different
patient-days on antimicrobials
Antimicrobial starts Sum of the calendar days on which each new
antimicrobial drug was started, following 3 or
more days without exposure to that drug
2 drugs given for 5 days followed by a different drug
given for 5 days to one patient = 3 antimicrobial starts
Antimicrobial courses Sum of the calendar days on which any
antimicrobial drug was started, following 3 or
more days without exposure to any antimicrobial
drug
2 drugs given for 5 days followed by a different drug
given for 5 days to one patient = 1 antimicrobial course
Defined daily doses (DDDs) World Health Organization-standardized
conversion of aggregate drug dosing data into
number of doses26
200 grams of vancomycin dispensed divided by 2
grams per vancomycin DDD = 100 DDDs of
vancomycin
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Table 3
Logic Used in Computing Numerators Used in Antimicrobial Utilization Measures from Different
Computerized Data Sources
Data Source Events Measureda Logic Applied
Pharmacy dispensing Antimicrobial doses
dispensed from pharmacy
One or more doses of each antimicrobial dispensed during an ICU day
constitutes an antimicrobial day; one or more doses of any antimicrobial
dispensed during an ICU day constitutes a patient-day on antimicrobials.
Physician orders (CPOE) Antimicrobial start and stop
orders; ICU admission and
discharge days
ICU days on which each antimicrobial is ordered for continuous
scheduled administration and subsequent ICU days are counted as
antimicrobial days until either that drug’s iscontinuation d is ordered or
until ICU discharge. ICU days on which any antimicrobial is ordered and
subsequent ICU days are counted as patient-days on antimicrobials until
either the discontinuation of all antimicrobials has been ordered or until
ICU discharge.
Medication administration (eMAR Antimicrobial doses
administered by nurse
One or more doses of each antimicrobial administered during an ICU
day constitutes an antimicrobial day; one or more doses of any
antimicrobial administered during an ICU day constitutes a patient-day
on antimicrobials.
ICU day constitutes a patient-day on antimicrobials. Note. CPOE, computerized provider order entry; eMAR, electronic medication administration
record.
a
Numerator events are counted only through the calendar day before ICU discharge.
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Table 4
Antimicrobial Classification System
Drug Class Associated Antimicrobial Agents
Anti-Pseudomonals piperacillin-tazobactam, imipenem, meropenem, ceftazidime, cefipime, aztreonam, levofloxacin,
ciprofloxacin, gentamicin, tobramycin, amikacin
Anti-MRSA drug vancomycin (parenteral only), linezolid, daptomycin, quinopristin-dalfopristin
Anti-MSSA drugs oxacillin, nafcillin, dicloxacillin, clindamycin
Other beta-lactam drugs cefazolin, cephalexin, cefoxitin, ceftriaxone, penicillin, ampicillin, ampicillin-sulbactam, amoxicillin,
amoxicillin-clavulanate
Anti-Clostridium difficile drugs metronidazole (oral only), vancomycin (oral only)
Macrolides azithromycin, clarithromycin, erythromycin
Tetracyclines doxycycline, minocycline, tetracycline
Other antibacterials metronidazole (parenteral only), moxifloxacin, trimethoprim, trimethoprim-sulfamethoxazole
Antifungals amphotericin B deoxycholate, liposomal amphotericin B, fluconazole, itraconazole, voriconazole,
caspofungin, anidulafungin
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Table 5
Errors Encountered During Validation of Computed Antimicrobial Utilization Rates from Computerized Data
Sources





utilization rates in an ICU in
Hospital A after change to new
pharmacy computer system.
Unknown to study personnel, an
automated testing procedure added 233
cefazolin days over 7 months to non-
existent patients.
Test entries were removed, with
revised cefazolin utilization rates
more comparable to rates





antimicrobial utilization rates in
Hospital A after change to new
pharmacy computer system.
Errant programming of ADT data in
new system led to inappropriate
attribution to the ICU stay of
antimicrobial use that occurred
following transfer from the ICU.
Programming was revised to limit
numerator events to ICU patient-
days as defined by the ADT
tables and new results were
validated.
3. Pharmacy dispensing Patient-days on antimicrobials
were calculated incorrectly,
with rates exceeding the
maximum 1,000 patient-days
on antimicrobials per 1,000
ICU patient-days in Hospital C.
The programmer misunderstood the
definition of patient-days on
antimicrobials.
Rates were corrected and







utilization rates in an ICU in
Hospital B.
Communication error led to
programming of ICU antimicrobial
recipients only, rather than all ICU
patients, in computing denominator
data.
Rates were reprogrammed to
include all ICU patients and new
results were validated.
2. Pharmacy dispensing Spuriously low antimicrobial
utilization rates in one ICU in
Hospital C.
Summed denominator days from two
parallel nursing units comprising an
ICU were used to calculate
antimicrobial use rates for each nursing
unit instead of calculating denominator
ICU days from each nursing unit
separately.
Rates were re-computed and
validated after the programmer
was made familiar with physical
layout of the ICU.
Note. CPOE, computerized provider order entry; eMAR, electronic medication administration record.
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Table 7
Potential Sources of Error in Computing Antimicrobial Use Rates from Computerized Pharmacy Data and
Suggestions for Avoiding Them
Potential Sources of Error Suggested Solutions
Data request/acquisition
Programmer’s understanding of clinical
concepts and goals underlying
investigator’s request for data may be
incomplete.
• Written request for data must clearly outline clinical concepts and goals.
• Programmer should have frequent access to investigator to clarify conceptual issues
Programmer’s understanding of the
physical context and clinical processes
and procedures relevant to the request
for data may be incomplete.
• The programmer should tour site(s) of care being studied.
• The programmer should be oriented to the processes of care relevant to the request for
data (e.g., hospital processes of medication ordering, distribution and administration)
emphasizing the point(s) at which the computerized data being studied are generated.
Investigator’s understanding of data
structure and programming procedures
may be limited.
• Programmer should describe proposed approach to request for data, including
anticipated shortcomings in data structure or availability, to investigator before writing
program code.
• Programmer should review program code with investigator before executing
programming procedures.
Data analysis
Computerized data may require careful
review for outlier entries and may
require re-formatting (e.g., converting
free text to categorical tabular entries)
before programming is possible.
• Programmer should involve investigator in review of data tables and obtain
investigator’s guidance in interpreting outlier entries.
• Magnitude of data cleaning and conversion efforts must be estimated and the necessary
resources - primarily personnel time - allocated.
• Investigator must assist in designing data restructuring plan and provide necessary
nomenclature and definitions.
Data validation
Investigator’s predisposition to trust
integrity of programming processes and
data derived thereby (“if it’s on a
computer screen, it must be right”) may
be misguided.
• Reports based on queries of computerized data must be carefully reviewed for face
validity:
➢ Are all expected data elements (e.g., antimicrobial names) represented?
➢ Are results comparable to previously validated data, if available?
➢ Do the results reflect anticipated variation?
• Reports based on queries of computerized data require validation, ideally via manual
comparison of samples of computerized data with an acceptable gold standard.
• Systematic sources of error must be vigorously sought to explain recurring or
substantial discrepancies in the results of these comparisons.
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